VSTM vs. MEIP, EPZM, CDXS, RIGL, ACHV, SGMO, AGEN, RGLS, FBIO, and CRIS
Should you be buying Verastem stock or one of its competitors? The main competitors of Verastem include MEI Pharma (MEIP), Epizyme (EPZM), Codexis (CDXS), Rigel Pharmaceuticals (RIGL), Achieve Life Sciences (ACHV), Sangamo Therapeutics (SGMO), Agenus (AGEN), Regulus Therapeutics (RGLS), Fortress Biotech (FBIO), and Curis (CRIS). These companies are all part of the "medical" sector.
Verastem (NASDAQ:VSTM) and MEI Pharma (NASDAQ:MEIP) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, community ranking, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability.
In the previous week, Verastem had 3 more articles in the media than MEI Pharma. MarketBeat recorded 15 mentions for Verastem and 12 mentions for MEI Pharma. Verastem's average media sentiment score of 0.19 beat MEI Pharma's score of -0.15 indicating that Verastem is being referred to more favorably in the media.
88.4% of Verastem shares are held by institutional investors. Comparatively, 52.4% of MEI Pharma shares are held by institutional investors. 2.2% of Verastem shares are held by insiders. Comparatively, 3.9% of MEI Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
MEI Pharma has higher revenue and earnings than Verastem. Verastem is trading at a lower price-to-earnings ratio than MEI Pharma, indicating that it is currently the more affordable of the two stocks.
MEI Pharma's return on equity of 48.32% beat Verastem's return on equity.
Verastem has a beta of 0.19, suggesting that its stock price is 81% less volatile than the S&P 500. Comparatively, MEI Pharma has a beta of 0.86, suggesting that its stock price is 14% less volatile than the S&P 500.
Verastem presently has a consensus price target of $20.21, suggesting a potential upside of 582.92%. MEI Pharma has a consensus price target of $7.00, suggesting a potential upside of 96.63%. Given Verastem's stronger consensus rating and higher probable upside, research analysts plainly believe Verastem is more favorable than MEI Pharma.
Verastem received 215 more outperform votes than MEI Pharma when rated by MarketBeat users. Likewise, 65.08% of users gave Verastem an outperform vote while only 61.11% of users gave MEI Pharma an outperform vote.
Summary
Verastem beats MEI Pharma on 9 of the 17 factors compared between the two stocks.
Get Verastem News Delivered to You Automatically
Sign up to receive the latest news and ratings for VSTM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VSTM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Verastem Competitors List
Related Companies and Tools
